P888: MATCHED-ADJUSTED INDIRECT COMPARISON OF TALQUETAMAB VS SELINEXOR-DEXAMETHASONE AND VS BELANTAMAB MAFODOTIN IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA
Ajai Chari,
Joris Diels,
Suzy Van Sanden,
Lixia Pei,
Eric Ammann,
Christoph Heuck,
Colleen Kane,
Anil Londhe,
Steve Peterson,
Donna Reece
Affiliations
Ajai Chari
1 Mount Sinai School of Medicine, New York, United States
Joris Diels
2 Janssen Pharmaceutica NV, Beerse, Belgium
Suzy Van Sanden
2 Janssen Pharmaceutica NV, Beerse, Belgium
Lixia Pei
3 Janssen Research & Development, Raritan, United States
Eric Ammann
4 Janssen Global Services, Raritan, United States
Christoph Heuck
5 Janssen Research & Development, Spring House, United States
Colleen Kane
5 Janssen Research & Development, Spring House, United States
Anil Londhe
6 Janssen Research & Development, Titusville, United States
Steve Peterson
7 Janssen Research & Development, Horsham, United States
Donna Reece
8 Princess Margaret Cancer Centre, Toronto, Canada